New medicine to help prevent kidney transplant rejection
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new medicine called TNX-1500 that may help prevent the body from rejecting a new kidney. It is for people who are already waiting for a kidney transplant and aims to make the transplant more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must be on the waiting list for a kidney transplant.
- You must have had a past Epstein-Barr virus infection (most adults have this).
- You cannot have had a previous organ transplant.
- You cannot have had cancer (except for a minor skin cancer).
- You must have normal heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
This study tests whether continuing certain anti-rejection medicines while on dialysis can help lower the risk of your immune system becoming too sensitive to a future kidney transplant. It might help you stay eligible for another transplant later.
This trial is testing a new blood test (called TreaT-Assay) to help diagnose acute rejection after a kidney transplant. The goal is to catch rejection earlier and more accurately, so you can get the right treatment faster.
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This study looks at whether Envarsus XR helps prevent “subclinical” (not obviously noticeable) kidney transplant rejection by changing blood immune test results. You may be able to join if you recently received a kidney transplant and can take the study medicine as required.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.